A Double-Blind, Randomised, Cross-Over, Placebo-Controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6.

Trial Profile

A Double-Blind, Randomised, Cross-Over, Placebo-Controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Ispronicline (Primary) ; Donepezil
  • Indications Alzheimer's disease; Cognition disorders; Dementia; Vascular dementia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2009 Planned end date changed from 1 May 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top